Pulmonary Fibrosis
Also known as: IPF, Idiopathic pulmonary fibrosis, Respiratory, Respiration, Pulmonary
Methodology & AI Transparency ⓘ
Pulmonary Fibrosis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Pulmonary fibrosis is a condition in which the tissue deep in your lungs becomes scarred over time.
- 2 Real-world patient consensus: Mapped to Asthma, COPD & Respiratory Disease under ICD-10-CM J84.10 for Pulmonary Fibrosis clinical workups.
- 3 Typical cash cost range: Differential triage of Pulmonary Fibrosis (J84.10) utilizes high-resolution chest imaging in Pulmonary Fibrosis (J84.10: when indicated).
- 4 Top reported side effects / signs: Objective lab/clinical target for Pulmonary Fibrosis: Resting Pulse Oximetry in Pulmonary Fibrosis (J84.10: (SpO2)) (96% – 100% (J84.10)) and Blood Eosinophil Count [Pulmonary Fibrosis J84.10].
Ask our AI Specialists anything about Pulmonary Fibrosis
What Is Pulmonary Fibrosis?
Pulmonary fibrosis is a condition in which the tissue deep in your lungs becomes scarred over time. This tissue gets thick and stiff. That makes it hard for you to catch your breath, and your blood may not get enough oxygen. Causes of pulmonary fibrosis include environmental pollutants, some medicines, some connective tissue diseases, and interstitial lung disease. Interstitial lung disease is the name for a large group of diseases that inflame or scar the lungs. In most cases, the cause cannot be found. This is called idiopathic pulmonary fibrosis.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Pulmonary Fibrosis (ICD-10 J84.10) is driven by mucus goblet-cell hyperplasia [Pulmonary Fibrosis J84.10]; Cross-referenced with NIH MeSH (Pulmonary Fibrosis), specialists in Asthma, COPD & Respiratory Disease monitor Blood Eosinophil Count [Pulmonary Fibrosis J84.10] to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Shortness of breath
- • A dry, hacking cough that doesn't get better
- • Presentation of Pulmonary Fibrosis (J84.10): prolonged recovery from in Pulmonary Fibrosis (J84.10: viral respiratory infections)
- • Secondary Pulmonary Fibrosis clinical sign: declining stair-climbing stamina in Pulmonary Fibrosis (J84.10: or frequent rescue)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Pulmonary Fibrosis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | J84.10 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Asthma, COPD & Respiratory Disease | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Resting Pulse Oximetry in Pulmonary Fibrosis (J84.10: (SpO2)) | 96% – 100% (J84.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Blood Eosinophil Count [Pulmonary Fibrosis J84.10] | < 150 cells/uL (phenotyping marker) (J84.10) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Spirometry FEV1 / in Pulmonary Fibrosis (J84.10: FVC Ratio) | >= 0.75 (FEV1 >= 80% predicted) (J84.10) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pulmonary Fibrosis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Vanzacaftor, Tezacaftor, and Deutivacaftor Alyftrek • RxCUI RXN-51167121-3011 | Cystic Fibrosis Transmembrane Conductance Regulator Potentiator | 83% | $1.7800 | $ 80.59 /mo |
| Tezacaftor and Ivacaftor Symdeko • RxCUI 1243046 | FDA Prescription Therapeutic Agent | 81% | $3.0000 | $ 130.00 /mo |
| Water Sterile Diluent for Treprostinil, Pur-Wash • RxCUI 349407 | Prostacycline Vasodilator | 85% | $0.2350 | $ 18.02 /mo |
| Treprostinil Tyvaso, Tyvaso Dpi • RxCUI 857795 | Prostacycline Vasodilator | 79% | $2.4600 | $ 108.13 /mo |
| Macitentan Opsumit • RxCUI 1442137 | Endothelin Receptor Antagonist | 90% | $1.7000 | $ 62.50 /mo |
| Xenon Xe-133 Xenon Xe-133 Generic • RxCUI RXN-87333127-1735 | Inhalation Diagnostic Agent | 87% | $1.9600 | $ 87.88 /mo |
| Ambrisentan Letairis • RxCUI 722116 | Endothelin Receptor Antagonist | 79% | $7.2410 | $ 185.00 /mo |
| Ethambutol Hydrochloride Myambutol • RxCUI 995599 | Antimycobacterial | 94% | $0.3008 | $ 9.73 /mo |
| Bosentan Tracleer • RxCUI 349253 | Endothelin Receptor Antagonist | 90% | $1.4700 | $ 68.03 /mo |
| Epoprostenol Veletri • RxCUI 562501 | Prostacycline Vasodilator | 93% | $2.4900 | $ 109.35 /mo |
| Ivacaftor Kalydeco • RxCUI RXN-51167300-2525 | Cystic Fibrosis Transmembrane Conductance Regulator Potentiator | 92% | $0.4400 | $ 26.32 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pulmonary Fibrosis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Sildenafil for congenital heart diseases induced lung high blood pressure, a: What a 849-Participant Study Found Sildenafil is a well-tolerated treatment in congenital heart diseases induced lung high blood pressure, as it has proven its efficacy not only in lowering both PAP mean and systolic but also in reducing the ventilation time,... BMC pediatrics • 2023-07-20 • Meta-Analysis | N = 849 | 97/100 | PMID 37474896 ↗ |
| New Insights on Relationship Between Time From Diagnosis and Morbidity/Mortality in lung Arterial: What a 1,156-Participant Study Found In the GRIPHON study, newly diagnosed PAH patients had a worse prognosis than patients with a longer time from diagnosis. Chest • 2021-07-15 • Phase III Randomized Trial | N = 1,156 | 96/100 | PMID 33545163 ↗ |
| New Insights on Effect of ensifentrine on dyspnea in patients with moderate-to-severe chronic: What a 975-Participant Study Found Ensifentrine produced clinically meaningful improvements in multiple dyspnea measures in patients with symptomatic, moderate-to-severe COPD. Expert review of respiratory medicine • 2024-08-15 • Phase III Randomized Trial | N = 975 | 93/100 | PMID 39106052 ↗ |
| What the Latest Evidence Really Says About Vasodilators for persistent lung high blood pressure of the newborn: A network Milrinone, Sildenafil, and Sildenafil_Milrinone reduced the mortality of neonates with PPHN. Pediatric pulmonology • 2024-12-15 • Meta-Analysis | Multi-cohort | 92/100 | PMID 39193897 ↗ |
| Can This Approach Help? Inside the Latest Research on Effect of melatonin administration on subjective sleep quality in chronic We conclude that melatonin can improve sleep in COPD. Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas • 2008-10-15 • Randomized Controlled Trial | N = 12 | 88/100 | PMID 19030713 ↗ |
Pulmonary Fibrosis Patient Community & “People Like Me” Threads
Filter Pulmonary Fibrosis community threads and patient logs by age, biological sex, dosage, and treatment duration.